The role of the IGF pathway as a potential target for treatment in ACC might have been overestimated, as suggested by the fact that up-to-date in vivo experiments demonstrated that isolated IGF2 overexpression has no oncogenic potential [47]. The gene discussed is IGF2; the disease is adrenal cortex carcinoma.